New blood test aims to detect deadly esophageal cancer before It's too late

NCT ID NCT07266363

Recruiting now Diagnosis Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

The SYNERGY study is developing a blood test that looks for tiny genetic molecules called microRNAs to detect esophageal squamous cell carcinoma (ESCC) at an early, more treatable stage. Researchers will collect blood samples from 600 adults with and without ESCC to build and validate a diagnostic model. If successful, this non-invasive test could replace or complement current invasive screening methods like endoscopy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Blood-based microRNA assay (SYNERGY assay)
What this could lead to: If successful, this could lead to a simple blood test that catches esophageal cancer early, when it is more treatable, potentially saving lives.
What could go wrong: This is an early-stage study with 600 participants, so the test may not prove accurate enough for widespread use. It is not yet ready for clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESCC

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Monrovia, California, 91016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.